Tuesday, 02 January 2024 12:17 GMT

Biostem Technologies To Present At The 16Th Annual LD Micro Invitational


(MENAFN- GlobeNewsWire - Nasdaq) POMPANO BEACH, Fla., May 12, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that Company management will present at the 16th Annual LD Micro Invitational in Los Angeles, CA.

BioStem's management is scheduled to present on Monday, May 18, 2026, at 1:30 PM ET. Interested parties may access live and archived webcasts of the presentations on the“investors” section of the Company's website at: biostemtechnologies.

About BioStem Technologies, Inc. (OTC: BSEM): BioStem Technologies is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain®, CryoTek®and SteriTek®processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Its allografts are used by clinicians across a wide range of specialties. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine.

BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established in compliance with current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). BioStem's portfolio of quality brands includes its Neox®, Clarix®, VENDAJE®and American AmnionTM product lines.

Join BioStem's Distribution List & Social Media:
To follow the latest developments at BioStem, sign up for the Company's email distribution list HERE, and follow us on X and LinkedIn.

Contact BioStem:
Website:
E-Mail: ...
X: @BSEM_Tech
Facebook: BioStemTechnologies
Phone: 954-380-8342

Investor Relations:
Philip Trip Taylor, Gilmartin
Group E-Mail: ...

Public Relations:
Jennifer Horton, Relevance
...


MENAFN12052026004107003653ID1111105477



GlobeNewsWire - Nasdaq

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Search